AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist
Positive Clinical Update On Evusheld
AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.
